Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

Author： van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

Publisher： Elsevier

ISSN： 0302-2838

Source： European Urology, Vol.41, Iss.1, 2002-01, pp. : 54-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension

By Chatelain C.   Autet W.   Brackman F.  

Urology, Vol. 54, Iss. 3, 1999-09 ,pp. : 473-478

Elsevier

Access to resources Recommend Favorite

First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia

By Marks L.S.   Roehrborn C.G.   Gittelman M.   Kim D.   Forrest J.   Jacobs S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 888-893

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial 1

By Roehrborn C.G.   for the ALFUS STUDY GROUP  

Urology, Vol. 58, Iss. 6, 2001-12 ,pp. : 953-959

Elsevier

Access to resources Recommend Favorite

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia

By Lepor H.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 406-413

Elsevier

Access to resources Recommend Favorite

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

By Lam J.S.   Romas N.A.   Lowe F.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 354-358

Elsevier

Access to resources Recommend Favorite